EUVIMEDEUVIMED entdecken
Crossref

Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity

Shaobo Mo, Wenqin Luo, Jiajun Yang, Xingfeng He, Maoguang Ma, Xin Cai, Yaqi Li, Xiang Hu, Peiyuan Mu, Sanjun Cai, Xiaoji Ma, Fangqi Liu und 3 weitere

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Shaobo Mo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medica…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Organoids, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: BRAFV600E-mutant colorectal cancer (CRC) represents an aggressive molecular subtype characterized by poor prognosis and resistance to standard therapies. Predictive models to guide treatment selection and overcome drug resistance are urgently needed. METHODS: We established a biobank of patient-derived organoids (PDOs) and matched xenografts (PDOXs) from BRAFV600E-mutant CRC, capturing inter- and intratumoral heterogeneity. PDOs were characterized by histopathology, whole-exome sequencing, bulk and single-cell RNA sequencing, and drug sensitivity testing to chemotherapies and targeted agents. Immunogenicity was assessed via PDO-T cell co-culture and humanized xenograft models. RESULTS: PDOs faithfully preserved parental tumor histology, mismatch repair status, mutational landscapes, and copy number alterations (91.6% concordance in driver genes). Single-cell transcriptomics confirmed high fidelity between PDOs and original tumors. Drug sensitivity assays revealed marked interpatient heterogeneity and accurately recapitulated clinical responses to FOLFIRI, FOLFOXIRI, and BRAF/EGFR inhibitor combinations. Notably, RNF43-mutant PDOs exhibited significantly enhanced sensitivity to encorafenib plus cetuximab. Integrative transcriptomic analysis (TCGA and PDO cohorts) identified that RNF43 mutations are associated with upregulation of E2F, G2M, interferon-α/γ, and inflammatory pathways, along with elevated MHC-I expression. In co-culture with CD8⁺ T cells, RNF43-mutant PDOs triggered stronger T-cell activation, enhanced cytotoxicity, and increased tumor cell apoptosis. In humanized PDOX models, RNF43-mutant tumors showed suppressed growth and heightened CD8⁺ T-cell infiltration compared to wild-type controls. CONCLUSIONS: This functional precision oncology platform integrates multi-omics and immune co-culture to uncover RNF43 mutation as a dual biomarker for targeted therapy sensitivity and tumor immunogenicity in BRAFV600E-mutant CRC. Our findings provide mechanistic rationale for combining BRAF/EGFR inhibition with immunotherapy to overcome drug resistance and improve outcomes in this aggressive subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafColorectal NeoplasmsOrganoidsUbiquitin-Protein LigasesDNA-Binding ProteinsHumansAnimalsMutationPrecision MedicineMiceXenograft Model Antitumor AssaysDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsCoculture Techniques

Stichwörter der Autor:innen

BRAF(V600E)-Mutated Colorectal CancerImmunogenicityPatient-derived organoidRNF43Targeted therapy

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanRNF43 protein, humanUbiquitin-Protein LigasesDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: shao…
  • Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Cancer Institute, Fudan…
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. Electronic address: hexigan…

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Mo, S., Luo, W., Yang, J., He, X., Ma, M., Cai, X., Li, Y., Hu, X., Mu, P., Cai, S., Ma, X., Liu, F., He, X., Zou, H., & Peng, J. (2026). Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101414

Vancouver

Mo S, Luo W, Yang J, He X, Ma M, Cai X, et al. Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101414

BibTeX
@article{Mo2026,
  author = {Mo, Shaobo and Luo, Wenqin and Yang, Jiajun and He, Xingfeng and Ma, Maoguang and Cai, Xin and Li, Yaqi and Hu, Xiang and Mu, Peiyuan and Cai, Sanjun and Ma, Xiaoji and Liu, Fangqi and He, Xigan and Zou, Hai and Peng, Junjie},
  title = {Functional precision oncology platform of BRAFV600E-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101414}
}
Kostenlos starten →